|
POP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.25110000026574E-07 |
| Normal-vs-Stage3 |
6.99440505513849E-15 |
| Normal-vs-Stage4 |
3.54716256367738E-12 |
| Stage1-vs-Stage2 |
5.057600E-01 |
| Stage1-vs-Stage3 |
9.348400E-02 |
| Stage1-vs-Stage4 |
6.230400E-02 |
| Stage2-vs-Stage3 |
1.023630E-01 |
| Stage2-vs-Stage4 |
6.372300E-02 |
| Stage3-vs-Stage4 |
6.138600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.78739997749966E-09 |
| Normal-vs-Asian |
4.22220000073636E-08 |
| Caucasian-vs-AfricanAmerican |
7.296600E-01 |
| Caucasian-vs-Asian |
4.919600E-01 |
| AfricanAmerican-vs-Asian |
4.802200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.99680288865056E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.226000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.19699805622986E-11 |
| Normal-vs-Age(41-60Yrs) |
4.10782519111308E-15 |
| Normal-vs-Age(61-80Yrs) |
2.13440376484186E-12 |
| Normal-vs-Age(81-100Yrs) |
4.101200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.341000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.853800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.097200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.711400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.165000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.371800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.269900E-02 |
| Classical-VS-Follicular |
2.131600E-01 |
| Classical-VS-Other |
1.679000E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
4.954200E-01 |
| Tall-VS-Other |
6.827800E-01 |
| Tall-VS-Normal |
1.63979996248287E-09 |
| Follicular-VS-Other |
4.619200E-01 |
| Follicular-VS-Normal |
1.7081003278463E-11 |
| Other-VS-Normal |
1.374250E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
7.1554984160116E-12 |
| N0-vs-N1 |
3.057400E-01 |
|
|
